Long-Term Clinical Outcomes of Treatments for In-Stent Chronic Total Occlusions: A Real-World Study Based on Different Strategies of Revascularization

Abstract

Coronary artery disease (CAD), the most common panvascular disease, can progress to chronic total occlusion (CTO). Drug-eluting stent (DES) is one of standard CAD treatments, but in-stent restenosis leading to CTO is challenging, with unclear optimal management. The efficacy of drug-coated balloons (DCB) for treating DES-related in-stent chronic total occlusion (IS-CTO) is undetermined. In this single-center retrospective cohort study of 198 patients with IS-CTO post-DES, 3-year outcomes of DCB, DES, and plain old balloon angioplasty (POBA) were compared, focusing on target vessel failure (TVF). DES showed the lowest TVF rate (DCB vs. DES vs. POBA: 31.8% vs. 17.1% vs. 51.6%, p < 0.01), mainly due to fewer revascularizations. Notably, the difference in TVF between DCB and DES became more apparent after the first year. DCB was an independent risk factor for late TVF (HR_adj = 6.51, 95% confidence interval [CI] = 2.45–18.84, p < 0.01), whereas POBA for early TVF compared to DCB (HR_adj = 5.01, 95% CI = 1.36–18.42, p = 0.02). While POBA-treated patients exhibited a higher target vessel myocardial infarction rate, the death rates were comparable across all cohorts. In conclusion, DES showed the lowest 3-year TVF rate, making it the most effective treatment for IS-CTO compared to DCB and POBA.

Keywords

coronary artery disease / drug-coated balloon / drug-eluting stent / in-stent chronic total occlusion / percutaneous coronary intervention / plain old

References

[1] X.Zhou, L.Yu, Y.Zhao, and J. Ge, “Panvascular Medicine: An Emerging Discipline Focusing on Atherosclerotic Diseases,” European Heart Journal 43, no. 43 (2022):4528–4531.

[2] Y.Hu, Y.Zhao, N.Dai, H. Lu, and J.Ge, “Unwavering Excellence: How to Be a Competent Cardiovascular Doctor in “Panvascular Medicine+,” The Innovation 4, no. 5 (2023):100489.

[3] M.Wong, Y.Dai, and J.Ge, “Pan-Vascular Disease: What We Have Done in the Past and What We Can Do in the Future?,” Cardiol Plus 9, no. 1 (2024):1–5.

[4] Y.Hu, Y.Zhao, P.Li, H.Lu, H.Li, and J.Ge, “Hypoxia and Panvascular Diseases: Exploring the Role of Hypoxia-Inducible Factors in Vascular Smooth Muscle Cells Under Panvascular Pathologies,” Science Bulletin 68, no. 17 (2023):1954–1974.

[5] Y.Zhao, W.Xiong, C.Li, et al., “Hypoxia-Induced Signaling in the Cardiovascular System: Pathogenesis and Therapeutic Targets,” Signal Transduction and Targeted Therapy 8, no. 1 (2023):431.

[6] J.Cuesta, M. J.Pérez-Vizcayno, B.García Del Blanco, et al., “Long-Term Results of Bioresorbable Vascular Scaffolds in Patients With In-Stent Restenosis,” JACC: Cardiovascular Interventions 17, no. 15 (2024):1825–1836.

[7] J. B.Ge, L.Ge, Y.Huo, J. Y. Chen, W. M.Wang, and B.Zhang, “Updated Algorithm of Chronic Total Occlusion Percutaneous Coronary Intervention From Chronic Total Occlusion Club China,” Cardiology Plus 6, no. 2 (2021):81–87.

[8] H.Lu, Y.Hu, Y.Ma, et al., “Exploring Indicators of Success in Chronic Total Occlusion Percutaneous Coronary Intervention With Stingray System-Based Antegrade Dissection Re-Entry: Insights From Retrospective Analysis,” Catheterization and Cardiovascular Interventions 102, no. 7 (2023):1210–1221.

[9] E.Barbato, E.Shlofmitz, A.Milkas, R.Shlofmitz, L.Azzalini, and A.Colombo, “State of the Art: Evolving Concepts in the Treatment of Heavily Calcified and Undilatable Coronary Stenoses - From Debulking to Plaque Modification, a 40-Year-Long Journey,” EuroIntervention 13, no. 6 (2017):696–705.

[10] R.Mehran, G.Dangas, A. S.Abizaid, et al., “Angiographic Patterns of In-Stent Restenosis: Classification and Implications for Long-Term Outcome,” Circulation 100, no. 18 (1999):1872–1878.

[11] J. W.Jukema, J. J. W. Verschuren, T. A. N.Ahmed, and P. H. A.Quax, “Restenosis after PCI. Part 1: Pathophysiology and Risk Factors,” Nature Reviews Cardiology 9, no. 1 (2012):53–62.

[12] S.Bangalore, S.Kumar, M.Fusaro, et al., “Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials,” Circulation 125, no. 23 (2012):2873–2891.

[13] A. R.Galassi, G. S.Werner, M.Boukhris, et al., “Percutaneous Recanalisation of Chronic Total Occlusions:2019 Consensus Document From the EuroCTO Club,” EuroIntervention 15, no. 2 (2019):198–208.

[14] F.Alfonso, R. A.Byrne, F.Rivero, and A. Kastrati, “Current Treatment of In-Stent Restenosis,” Journal of the American College of Cardiology 63, no. 24 (2014):2659–2673.

[15] R. A.Byrne, F. J.Neumann, J.Mehilli, et al., “Paclitaxel-Eluting Balloons, Paclitaxel-Eluting Stents, and Balloon Angioplasty in Patients With Restenosis After Implantation of a Drug-Eluting Stent (ISAR-DESIRE 3): A Randomised, Open-Label Trial,” Lancet 381, no. 9865 (2013):461–467.

[16] M.Unverdorben, C.Vallbracht, B.Cremers, et al., “Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis: The Three-Year Results of the Pepcad II ISR Study,” EuroIntervention 11, no. 8 (2015):926–934.

[17] B.Xu, J.Qian, J.Ge, et al., “Two-Year Results and Subgroup Analyses of the P EPCAD China In-Stent Restenosis Trial: A Prospective, Multicenter, Randomized Trial for the Treatment of Drug-Eluting Stent In-Stent Restenosis,” Catheterization and Cardiovascular Interventions 87, no. S1 (2016):624–629.

[18] F.Alfonso, M. J.Pérez-Vizcayno, B.García Del Blanco, et al., “Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis,” JACC: Cardiovascular Interventions 9, no. 12 (2016):1246–1255.

[19] F.Alfonso, M. J.Pérez-Vizcayno, J.Cuesta, et al., “3-Year Clinical Follow-Up of the Ribs IV Clinical Trial,” JACC: Cardiovascular Interventions 11, no. 10 (2018):981–991.

[20] F. J.Neumann, M.Sousa-Uva, A.Ahlsson, et al, “2018 ESC/EACTS Guidelines on Myocardial Revascularization,” European Heart Journal 40, no. 2 (2019):87–165.

[21] L.Azzalini, R.Dautov, S.Ojeda, et al., “Procedural and Long-Term Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusion,” JACC: Cardiovascular Interventions 10, no. 9 (2017):892–902.

[22] P.Lamelas, L.Padilla, M.Abud, et al., “In-Stent Chronic Total Occlusion Angioplasty in the LATAM-CTO Registry,” Catheterization and Cardiovascular Interventions 97, no. 1 (2021): E34–E39.

[23] E.Vemmou, A. S.Quadros, J. A.Dens, et al., “In-Stent CTO Percutaneous Coronary Intervention,” JACC: Cardiovascular Interventions 14, no. 12 (2021):1308–1319.

[24] S.Habara, K.Kadota, T.Shimada, et al., “Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis,” Journal of the American College of Cardiology 66, no. 1 (2015):14–22.

[25] S.Basavarajaiah, S. Mitomo, S.Nakamura, et al., “Long-Term Outcome Following Percutaneous Intervention of Intra-Stent Coronary Occlusion and Evaluating the Different Treatment Modalities,” IJC Heart & Vasculature 34 (2021):100803.

[26] L. W.Klein, S.Nathan, A.Maehara, et al., “SCAI Expert Consensus Statement on Management of In-Stent Restenosis and Stent Thrombosis,” Journal of the Society for Cardiovascular Angiography & Interventions 2, no. 4 (2023):100971.

[27] T.Wang, H.Guan, T.Tian, et al., “Thirty-Day and 5-year Results of Percutaneous Coronary Intervention for In-Stent Restenotic Chronic Total Occlusion Lesions: Data From 2,659 Consecutive Patients,” Catheterization and Cardiovascular Interventions 97, no. S2 (2021):1016–1024.

[28] C.Li, Y.Shen, R.Xu, et al., “Evaluation of Preprocedural Laboratory Parameters as Predictors of Drug-Eluting Stent Restenosis in Coronary Chronic Total Occlusion Lesions,” Angiology 70, no. 3 (2019):272–278.

[29] B.Xu, R.Gao, J.Wang, et al., “A Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated Balloon Versus Paclitaxel-Eluting Stent for the Treatment of Drug-Eluting Stent In-Stent Restenosis,” JACC: Cardiovascular Interventions 7, no. 2 (2014):204–211.

[30] B.Scheller, Y. P.Clever, B.Kelsch, et al., “Long-Term Follow-Up After Treatment of Coronary In-Stent Restenosis With a Paclitaxel-Coated Balloon Catheter,” JACC: Cardiovascular Interventions 5, no. 3 (2012):323–330.

[31] M.Unverdorben, C.Vallbracht, B.Cremers, et al., “Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis,” Circulation 119, no. 23 (2009):2986–2994.

[32] S.Kufner, S.Cassese, M.Valeskini, et al., “Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis,” JACC: Cardiovascular Interventions 8, no. 7 (2015):877–884.

[33] H.Rittger, J.Brachmann, A. M.Sinha, et al., “A Randomized, Multicenter, Single-Blinded Trial Comparing Paclitaxel-Coated Balloon Angioplasty With Plain Balloon Angioplasty in Drug-Eluting Stent Restenosis,” Journal of the American College of Cardiology 59, no. 15 (2012):1377–1382.

[34] H.Rittger, M.Waliszewski, J.Brachmann, et al., “Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty,” JACC: Cardiovascular Interventions 8, no. 13 (2015):1695–1700.

[35] H.Yabushita, H.Kawamoto, Y.Fujino, et al., “Clinical Outcomes of Drug-Eluting Balloon for In-Stent Restenosis Based on the Number of Metallic Layers: The New Tokyo Registry,” Circulation: Cardiovascular Interventions 11, no. 8 (2018): e005935.

[36] H. S.Singh, A. J.Kirtane, and J. W.Moses, “Angiosculpt® Scoring Balloon Catheter: An Atherotomy Device for Coronary and Peripheral Interventions,” Interventional Cardiology 2, no. 4 (2010):469–478.

[37] F.Alfonso, M. J.Pérez-Vizcayno, A.Cárdenas, et al., “A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents,” Journal of the American College of Cardiology 66, no. 1 (2015):23–33.

[38] C.Hu, “Grants Supporting Research in China,” European Heart Journal 39, no. 25 (2018):2342–2344.

[39] D.Giacoppo, F.Alfonso, B.Xu, et al., “Paclitaxel-Coated Balloon Angioplasty vs. Drug-Eluting Stenting for the Treatment of Coronary In-Stent Restenosis: A Comprehensive, Collaborative, Individual Patient Data Meta-Analysis of 10 Randomized Clinical Trials (Daedalus Study),” European Heart Journal 41, no. 38 (2020):3715–3728.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).